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OBJECTIVE—The hypothalamus is the central brain region
responsible for sensing and integrating responses to changes in
circulating glucose. The aim of this study was to determine the
time sequence relationship between hypothalamic activation and
the initiation of the counterregulatory hormonal response to
small decrements in systemic glucose.
RESEARCH DESIGN AND METHODS—Nine nondiabetic vol-
unteers underwent two hyperinsulinemic clamp sessions in
which pulsed arterial spin labeling was used to measure regional
cerebral blood ﬂow (CBF) at euglycemia (95 mg/dl) on one
occasion and as glucose levels were declining to a nadir of 50
mg/dl on another occasion. Plasma glucose and counter-
regulatory hormones were measured during both study sessions.
RESULTS—CBF to the hypothalamus signiﬁcantly increased
when glucose levels decreased to 77.2  2 mg/dl compared with
the euglycemic control session when glucose levels were 95.7 
3 mg/dl (P  0.0009). Hypothalamic perfusion was signiﬁcantly
increased before there was a signiﬁcant elevation in counter-
regulatory hormones.
CONCLUSIONS—Our data suggest that the hypothalamus is
exquisitely sensitive to small decrements in systemic glucose
levels in healthy, nondiabetic subjects and that hypothalamic
blood ﬂow, and presumably neuronal activity, precedes the rise
in counterregulatory hormones seen during hypoglycemia.
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T
he brain relies on glucose as its main energy
substrate, and small decrements in circulating
glucose provoke an elaborate counterregulatory
hormonal feedback response (1,2). Activation of
the counterregulatory response requires effective detec-
tion of a falling glucose level. Although multiple glucose
sensors may be involved (3–7), the hypothalamus has
emerged as the dominant brain region responsible for
sensing and integrating responses to changes in circulating
glucose levels (8–12). Although most prior studies have
relied on animal models to study the neurophysiological
response to changes in glucose, newer imaging techniques
such as functional magnetic resonance imaging (fMRI) and
positron emission tomography (PET) provide an in vivo
method to study the effect of changes in peripheral glucose
levels on human brain activity. Several fMRI studies in
humans have demonstrated that a rise in systemic glucose
after glucose ingestion leads to an inhibition of hypotha-
lamic activity (13–16). In addition, Musen et al. (17)
recently used fMRI based on the blood oxygenation level–
dependent (BOLD) contrast mechanism and found that
insulin-induced hypoglycemia leads to hypothalamic acti-
vation. However, the fMRI-BOLD approach used in that
study assesses only relative changes in oxygenated hemo-
globin in speciﬁc brain regions and does not directly
measure tissue perfusion. Magnetic resonance imaging
(MRI) pulsed arterial spin labeling (PASL) provides a
method for measuring absolute blood ﬂow responses
throughout the brain to changes in circulating glucose
levels. PASL magnetically tags the arterial blood before
entering the brain and then examines the transit time for
the tagged blood to reach speciﬁc tissues, thereby provid-
ing a direct measure of cerebral blood ﬂow (CBF) (18–20).
Increased CBF has long been associated with neuronal
activation, dating back to the ﬁrst PET studies of brain
function (21).
Some studies, using PET (22), single-photon emission
computed tomography (23), high-ﬁeld magnetic resonance
perfusion (24), and continuous arterial spin labeling (25),
have shown region-speciﬁc increases in brain CBF in
response to hypoglycemia. However, none of these studies
speciﬁcally demonstrated changes in blood ﬂow to the
hypothalamus during hypoglycemia. Moreover, in these
studies, CBF measurements were performed after hypo-
glycemic levels had been achieved; thus, none of these
studies determined the CBF response to smaller decre-
ments in systemic glucose or the relationship between
regional brain activation and the initiation of the counter-
regulatory hormonal response.
We used PASL to determine the effect of small decre-
ments in circulating glucose on hypothalamic blood ﬂow
in healthy volunteers. We performed CBF measurements
as glucose levels were declining. This approach allowed us
to address the following questions: 1) Does a decline in
plasma glucose provoke hypothalamic activation? 2)I fs o ,
what is the plasma glucose level that correlates with
hypothalamic activation? 3) How does hypothalamic acti-
vation temporally relate to the counterregulatory hormone
response to hypoglycemia? An understanding of how the
hypothalamus, a key brain glucose-sensing region, re-
sponds to decrements in circulating glucose levels in
healthy humans provides critical information that can be
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diabetes, may alter this response.
RESEARCH DESIGN AND METHODS
Nine (eight men, one woman) healthy, nondiabetic subjects participated in
this study. Subject participants had a mean ( SD) age of 28  5 and a mean
(BMI of 23.6  2. Subjects underwent a screening history, physical examina-
tion, and laboratory testing, and only individuals with no history of signiﬁcant
disease, including diabetes, were included in the study. Exclusion criteria also
included any contraindications for MRI including pregnancy and metal
implants. Before each study session, female subjects were required to have a
negative urine pregnancy test. The Yale University School of Medicine Human
Investigation Committee approved this study, and all subjects provided
informed, written consent before participation in the study.
General experimental protocol
Subjects participated in two study sessions that were separated by a minimum
of 7 days. On the morning of the study, an intravenous catheter was inserted
into a distal arm or hand vein; this arm was gently heated, allowing for
sampling of arterialized venous blood. A second intravenous catheter was
established for the administration of insulin and glucose. During the 135-min
study sessions, a primed continuous infusion of intravenous insulin at 2 mU 
kg
1  min
1 was initiated, with a variable infusion of 20% glucose adjusted to
achieve euglycemia (plasma glucose 95 mg/dl) on one occasion and hypo-
glycemia (plasma glucose 50 mg/dl) on the other occasion. Regional CBF
measurements were performed using PASL at 30 min after the start of the
plasma glucose decline toward hypoglycemic levels and at 90 min during the
euglycemic session. Plasma glucose levels were measured at 5-min intervals,
and additional plasma samples were drawn at 20, 0, 30, 60, 120, and 135 min
for measurement of insulin, glucagon, catecholamines, cortisol, and growth
hormone. C-peptide was measured at 20-, 0-, 30-, and 60-min time points. The
two study sessions were carried out in a single-blind fashion, in variable order
across subjects.
fMRI imaging protocol
MRI was performed on a 3T Siemens Trio whole-body scanner (Siemens
Medical Systems, Erlangen, Germany) with a circularly polarized head coil.
PASL using the EPISTAR QUIPSS PASL MRI technique was used to measure
CBF. The PASL acquisition parameters were as follows: ﬁeld of view 256 
256 mm
2; matrix 60  64; bandwidth 2,298 Hz/pixel; slice thickness 6 mm; and
interslice spacing 3 mm. Ten anterior commissure/posterior commissure
(AC-PC) aligned slices were acquired from inferior to superior in an ascending
order. The whole imaging slab was positioned on the upper part of the brain,
with the lowest slice passing through AC-PC to acquire the top part of the
brain; the imaging slab positioned on the lower part of the brain with the
seventh slice from the bottom passing through AC-PC to acquire the bottom
part of the brain. Acquisition of each slice took 54 ms. The repetition time
(TR) was 3,000 ms; the echo time (TE) was 26 ms. During each echo planar
image acquisition, fat was suppressed and the phase-correction echoes were
collected and applied. A bipolar gradient of encoding velocity Venc  20 mm/s
was applied to the imaging slices for intravascular signal suppression.
To quantify regional CBF for both upper and lower parts of the brain, 2 vol
10–proton density–weighted images were acquired with the same perfusion
sequence, except for the following changes: TR  8,000 ms; TD  0 ms; TI 
7,375 ms; and TE  26 ms. Mapping for the apparent longitudinal relaxation
time Tlapp was performed with an ultra-fast Look-Locker echo-planar imaging
T1 mapping sequence.
Two additional image acquisitions were acquired to aid in multisubject
registration. First, a high-resolution whole-brain T1-weighted three-dimen-
sional image was acquired for each subject using magnetization prepared
rapid acquisition with gradient-echo imaging (MPRAGE), with the following
settings: 160 sagittal slices with ﬁeld of view  256  256 mm
2, voxel size 1 
1  1m m
3,T R 1,500 ms, TI  800 ms, TE  2.83 ms; ﬂip angle 15°, and 1
average. Second, two-dimensional T1-weighted images were acquired during
each magnetic resonance session using the same slice positions as the
perfusion-weighted images and the following additional settings: ﬁeld of
view  256  256 mm
2, in-plane resolution 1  1m m
2,T R 300 ms, TE 
3.69 ms, ﬂip angle 60°, and 2 averages.
fMRI imaging analysis
Preprocessing of PASL images. Perfusion-weighted and the proton
density–weighted images were motion corrected using the Statistical Para-
metric Mapping package (SPM99) via a six-parameter rigid-body transformation.
Calculation of absolute CBF. Perfusion-weighted images were obtained by
pairwise “surround” subtraction between interleaved label and control pairs
(18–20) while the subject was at rest, resulting in a complete perfusion map
every 2 TRs, i.e.,4si no u rcase. One perfusion-induced volume (M) was
calculated by performing the subtraction described in Eq. 1 (below) between
the tagged and untagged images. The mean image of the motion-corrected
proton density images, M0*, was also used for CBF mapping. The absolute
CBF f (ml  100 g
1  min
1) was calculated as follws:
Mt  M
ctrlt  M
labelt 
2cft  	aM0
*


e
t/T1a (1)
in which  is the tissue-blood partition coefﬁcient for water;
c  
1  e
(t 	 a)(1/T1app  1/T1a)
t  	a1/T1app  1/T1a)
(2)
is the correction factor, which accounts for exchange of labeled magnetiza-
tion from intravascular to extravascular space and clearance of the labeled
blood water out of the capillary bed; 	a is the arterial transit time, which is the
time for the labeled blood water to arrive at the capillary bed after labeling; and
M0
*  M0e
TE/T2
*
(3)
Tlapp is the apparent longitudinal relaxation time, which was estimated with an
ultrafast Look-Locker echo-planar imaging T1 mapping sequence (26).
Other parameters used in CBF quantiﬁcation are as follows: Tla  1,490 ms,

0.9 ml/g,   0.95, t 	 a  700 ms, and TI  1,400 ms for the ﬁrst slice.
The activation maps were obtained by contrasting the average CBF images
for two conditions. After M0*, Tlapp, and M have been measured on a
per-voxel basis, CBF (f) can then be estimated using Eq. 1.
Multisubject analysis. A standard whole brain template (MNI-1 mm) was
used for subject spatial normalization of the individual data. Subject integra-
tion and registration were carried out using the BioimageSuite software
package (http://www.bioimagesuite.org) (27) for the PASL images under
conditions of euglycemia and hypoglycemia. Two transformations were
calculated and used in multiple subject integration: 1) an afﬁne transformation
was estimated by coregistering the two-dimensional anatomical image to the
high-resolution three-dimensional anatomical image of each individual, and
this was then used to transform the individual maps of the resting state CBF
to the high-resolution three-dimensional anatomical space of that subject; and
2) a nonlinear transformation was used to coregister the high-resolution
three-dimensional anatomical image of each individual to the brain template,
which enabled warping of all the transformed maps of an individual subject
from step (1) to a common brain space. Tri-linear interpolation was used for
image regridding. The mean, SD, and other statistics were estimated in the
common template space on the pooled subject data. In this common reference
space, voxel-wise contrasts between conditions (euglycemia and hypoglyce-
mia) were estimated in the common space on the pooled subject data using a
t statistic to test the null hypothesis. Region of interest analysis was
performed on the hypothalamus.
Laboratory analyses
Plasma glucose was measured by an enzymatic reaction using glucose oxidase
(Yellow Springs Instruments, Yellow Springs, OH). Plasma concentrations of
insulin and glucagon were measured with the use of double-antibody radioimmu-
noassay (RIA) kits (Millipore, St. Charles, MO). Plasma epinephrine and norepi-
nephrine were measured by high-performance liquid chromatography (ESA,
Chelmsford, MA). Plasma growth hormone and cortisol were measured by RIA
(Irvine, CA; Diagnostic Products, Los Angeles, CA), and plasma C-peptide was
measured by use of double-antibody RIA kits (Diagnostic Products).
RESULTS
Plasma glucose and glucoregulatory hormone con-
centrations. Plasma glucose levels were not signiﬁcantly
different at baseline before the euglycemic and hypoglycemic
clamp sessions (Fig. 1; Table 1). In the euglycemic-hyperin-
sulinemic session, plasma glucose levels were indistinguish-
able from baseline values at the time of brain perfusion
acquisition. In the hypoglycemic-hyperinsulinemic session,
plasma glucose was gradually lowered over 60 min and then
was maintained at 52.8  0.6 mg/dl for the remainder of the
study (Fig. 1). During the hypoglycemic session, the brain
perfusion acquisition measurements were obtained at the
time of the slow glucose decline (30 min) when plasma
glucose averaged 77.2  2 mg/dl. During the euglycemic
session, brain perfusion measurements were performed at
90 min when plasma glucose averaged 95.7  3 mg/dl. As
shown in Fig. 1, steady-state plasma insulin levels during the
hypoglycemic and euglycemic sessions were not signiﬁcantly
different (123  9 vs. 124  10 
U/ml, respectively).
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obtained, plasma epinephrine, norepinephrine, cortisol,
and growth hormone were not altered during the hypogly-
cemic or euglycemic clamp study, but glucagon was
reduced from baseline during the euglycemic session (Fig.
2; Table 1). Subsequently, hypoglycemia provoked an in-
crease when compared with the euglycemic session in
plasma epinephrine (56  15 vs. 15  3 pg/ml, P  0.02 at
60 min), glucagon (88  13 vs. 49  7 pg/ml, P  0.006 at
90 min), and growth hormone (14.97  4 vs. 1.91  0.22
ng/ml at 90 min, P  0.01). Small increases in plasma
cortisol and norepinephrine were observed at 120 and 135
min, respectively (P  0.05).
In contrast to the counterregulatory hormones, the
small decline in plasma glucose at 30 min caused a
signiﬁcant fall in plasma C-peptide concentration from
0.47  0.02 to 0.34  0.02 pmol/ml (P  0.001). There was
a further reduction in C-peptide to 0.19  0.02 by 60 min.
In contrast, C-peptide did not signiﬁcantly change during
the euglycemic session.
Regional CBF response. Figure 3 shows the whole brain
mean difference map for the hypoglycemic compared with
the euglycemic session (P  0.05, uncorrected) that was
obtained when plasma glucose averaged 77.2  2 mg/dl.
This mild decrease in plasma glucose caused a signiﬁcant
increase in hypothalamic blood ﬂow. Region of interest
analysis demonstrated that mean hypothalamic perfusion
was twofold greater during the hypoglycemic session
(44.523 ml  100 g
1  min
1) than the euglycemic session
(21.990 ml  100 g
1  min
1)( P  0.0009) (Fig. 4). The right
anterior cingulate cortex, left caudate, left putamen, left
superior temporal gyrus, left inferior frontal gyrus (IFG),
and left visual association cortex (Broca’s area [BA] 18)
also exhibited increased blood ﬂow, whereas the cerebel-
lum, right pars opercularis (BA 44), and right medial
frontal gyrus (BA 46) exhibited decreased blood ﬂow
during the hypoglycemic session compared with the eu-
glycemic session (P  0.05) (Table 2). We used the
orbitofrontal cortex (OFC) as a control region and found
no difference in CBF to either the right OFC (hypoglyce-
mia, 16.229 ml  100 g
1  min
1; euglycemia, 18.509 ml 
100 g
1  min
1, P  0.35) or left OFC (hypoglycemia,
21.439 ml  100 g
1  min
1; euglycemia, 18.261 ml  100
g
1  min
1, P  0.2) during the hypoglycemic session
when compared with the euglycemic session.
DISCUSSION
We used PASL to quantify hypothalamic perfusion after small
decrements in circulating glucose in healthy human volun-
teers. PASL is an indirect measure of neuronal activity
believed to reﬂect changes in metabolic state because there
is a clear relationship between changes in the local rate of
oxygen consumption and changes in local tissue blood ﬂow
(20). Although previous studies have investigated the effects
of hypoglycemia on CBF in nondiabetic subjects, the current
study examined the effects of small glucose decrements
within the normal range, whereas earlier studies measured
CBF after moderate hypoglycemic levels (plasma glucose
60 mg/dl) were achieved (22,24,25). As a result, we were
able to investigate the time sequence relationship between
hypothalamic activation and the initiation of the counter-
regulatory hormonal response.
We focused our attention on the hypothalamic blood ﬂow
response to decrements in systemic glucose based on earlier
animal studies demonstrating the importance of hypotha-
lamic glucose-sensing neurons in hypoglycemia detection
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FIG. 1. A: Plasma glucose levels (in mg/dl) obtained during the euglycemic () and hypoglycemic (f) clamp sessions. B: Insulin levels were raised
comparably during euglycemic and hypoglycemic clamp sessions.
TABLE 1
Plasma glucose and counterregulatory hormones at baseline, approximate time of CBF acquisition for hypoglycemic and euglycemic
clamp sessions, and peak levels for the hypoglycemic session
Baseline Time of CBF acquisition Peak Baseline Time of CBF acquisition
Glucose (mg/dl) 93.1  3 77.2  2*† — 94.3  4 95.7  3
Epinephrine (pg/ml) 16  41 4  4 178  36* 13  31 4  3
Norepinephrine (pg/ml) 120  13 124  11 169  15* 136  15 123  10
Glucagon (pg/ml) 67  96 5  10† 117  20* 70  75 0  8*
Cortisol (mg/dl) 12.9  1.8 9.9  1.4 16.9  1.5 12.2  1.8 12.1  1.0
Growth hormone (ng/ml) 1.8  0.3 1.7  0.2 21.3  5.4* 3.1  1.0 2.9  0.7
Data are means  SE. *P  0.05 vs. baseline. †P  0.05 hypoglycemic vs. euglycemic session at time of CBF acquisition.
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sponses (8–11). Moreover, the hypothalamus plays a central
role in the regulation of appetite and energy expenditure—
responses known to be stimulated by hypoglycemia. Our
data are consistent with this hypothesis and with prior
studies using fMRI-BOLD demonstrating that the hypothala-
mus is responsive to changes in systemic glucose levels
(13–17). On the other hand, previous studies investigating the
effects of hypoglycemia on regional CBF in nondiabetic
subjects have not identiﬁed an increase in hypothalamic
blood ﬂow following insulin-induced hypoglycemia
(22,24,25). This may be because the hypothalamus is a very
small brain region, making it difﬁcult to detect signiﬁcant
changes in blood ﬂow when compared with larger brain
regions. We used PASL, which may have given us greater
spatial resolution than other methods for measuring CBF,
such as PET. In addition, unlike previous studies, we used
region of interest analysis focusing on the hypothalamus,
which may also have contributed to some of the differences
in regional CBF results in our study.
It is noteworthy that CBF increased in the hypothala-
mus after a very small reduction in glucose (from 93.1 
3 to 77.2  2 mg/dl) when compared with a euglycemic
control study. Our data are consistent with those of
Musen et al. (17), who used fMRI-BOLD and found a
slightly lower glucose threshold (plasma glucose 68  9
mg/dl) for hypothalamic activation in nondiabetic individu-
als. However, in that study, the relationship between the
onset of hypothalamic activation and systemic hormone
release was not examined. The current data show that
hypothalamic perfusion was signiﬁcantly increased before
glucose levels reached a point at which there was a signiﬁ-
cant elevation of counterregulatory hormones. Because the
acquisition of CBF measurements was limited to only one
time point during the euglycemic and hypoglycemic clamp
sessions, measurements of regional CBF at multiple time
points during euglycemic and hypoglycemic clamp sessions
will be required for more precise time course analyses of
hypothalamic activation and the counterregulatory hormonal
response. A potential limitation of the current study is that
CBF measurements were performed at 30 min during the
hypoglycemic session and at 90 min during the euglycemic
session. It is noteworthy, however, that plasma insulin levels
were higher at the 90-min time point during the euglycemic
session when compared with the 30-min time point during
the hypoglycemic session (124  10 vs. 90  13 mU/ml).
Insulin has known vasoactive effects, and a recent report by
Seaquist et al. (28) shows that insulin has direct vasodilatory
effects on cerebral vasculature in humans that are indepen-
dent of effects on neuronal activation. This suggests that
higher circulating insulin levels in the euglycemic study
session may increase regional CBF, which would be ex-
pected to attenuate the results that we observed in our study.
Therefore, it is unlikely that the changes in hypothalamic
CBF that we observed are due to measurement time differ-
ences. As has been previously reported (2), we observed a
fall in endogenous insulin secretion, as measured by C-
peptide, before there was a detectable rise in counterregula-
tory hormones. This occurred at plasma glucose levels that
were similar to those that stimulated hypothalamic blood
ﬂow. Although this ﬁnding does not establish a causal
relationship between hypothalamic activation and suppres-
sion of endogenous insulin secretion, it raises the possibility
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FIG. 2. Plasma epinephrine and glucagon response during hyperinsulinemic-euglycemic () and -hypoglycemic (f) sessions. *P < 0.05
hypoglycemic vs. euglycemic session.
Hypothalamus
cerebellum
IFG
FIG. 3. Saggital (left), coronal (middle), and axial (right) images
showing the mean difference (CBF euglycemia  CBF hypoglycemia)
map of CBF from nine subjects. Blue represents increased and yellow/
orange represents decreased blood ﬂow during the hypoglycemic ses-
sion relative to the euglycemic session. During hypoglycemia, ﬂow was
greater to the hypothalamus and left IFG and less to the cerebellum
(other regions are noted in Table 1; P < 0.05, uncorrected). (Please see
http://dx.doi.org/10.2337/db08-1224 for a high-quality digital represen-
tation of this ﬁgure.)
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FIG. 4. Hypothalamic perfusion: region of interest analysis showing
that blood ﬂow to the hypothalamus was signiﬁcantly higher during
hypoglycemia than euglycemia. *P  0.0009.
K.A. PAGE AND ASSOCIATES
DIABETES, VOL. 58, FEBRUARY 2009 451that these may be coordinated events. Whether there is a
neural or hormonal cue that may act to coordinate hypotha-
lamic activation and suppression of endogenous insulin
secretion as glucose levels are declining is unclear and will
require further investigation.
In summary, the present analysis suggests that the
hypothalamus, a key central glucose-sensing region, is
exquisitely sensitive to small decrements in systemic
glucose levels and that hypothalamic blood ﬂow and,
presumably, neuronal activity precede the rise in coun-
terregulatory hormones seen during hypoglycemia.
These data lay the groundwork for future studies to
determine how metabolic disorders, such as diabetes,
alter the hypothalamic response to changes in systemic
glucose.
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TABLE 2
Talairach coordinates for areas showing increased or decreased
activation during hypoglycemia relative to euglycemia at a
threshold of P  0.05 (uncorrected)
Brain region BA
Talairach
coordinates
XYZ
Response to
hypoglycemia
Left hypothalamus 3/6/8 Activation
Right hypothalamus 3/6/8 Activation
Right anterior
cingulate cortex 24/32 4/37/4 Activation
Left caudate 10/11/8 Activation
Left putamen 23/8/8 Activation
Left superior
temporal gyrus 22 54/0/4 Activation
Left pars triangularis 45 34/24/8 Activation
Left inferior frontal
gyrus 47 35/38/12 Activation
Left visual association
cortex 18 19/74/28 Activation
Right pars opercularis 44 50/3/20 Deactivation
Cerebellum 2/48/16 Deactivation
Right medial frontal
gyrus 46 38/40/16 Deactivation
HYPOTHALAMIC ACTIVATION
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